Significant progress has been made to elucidate the molecular mechanisms that determine thyroid tumor development and progression. However, most investigations have mainly focused on the genetic alterations of nuclear DNA. The potential role of mitochondrial DNA (mtDNA) mutations in thyroid tumorigenesis is not well defined. In the present study, we investigated the frequency of mtDNA mutations in 24 thyroid tumor specimens (19 primary papillary thyroid carcinomas (PTC), one follicular thyroid carcinoma, and four multinodular hyperplasias) and four thyroid cancer cell lines by sequencing the entire coding regions of mitochondrial genome. Among the 19 PTC samples tested, seven (36.8%) had somatic mutations. Somatic mtDNA mutations were also detected in one of four multinodular hyperplasias examined. All the thyroid tumor cell lines carried sequence variations that change amino acid and have not been reported previously as normal sequence variants. Flow cytometry analysis of mitochondria respiratory function in the thyroid tumor cell lines revealed a severe defect in mitochondrial complex I activity. The majority of the mutations was involved in genes located in the complex I of the mitochondrial genome. The mutations were either A-G or C-T transitions, often resulting in a change of a moderately or highly conserved amino acid of their corresponding protein. These data suggest that mtDNA mutations may play an important role in the thyroid tumorigenesis. Given that mtDNA mutation is present in the benign multinodular hyperplasia, it might be involved in the early stage of tumor development. Keywords: mitochondria; mutation; thyroid neoplasm; respiratory function Although thyroid carcinoma represents only 1% of all malignant diseases, it is the most common malignancy of the endocrine system, and accounts for the majority of deaths from endocrine cancers (Mazzaferri, 1993; Schmutzler and Koehrle, 2000) . As in most solid tumors, the malignant transformation of thyroid epithelial cells is thought to arise through multiple genetic changes involving the activation of proto-oncogenes and the loss of tumor suppressor genes by point mutation, deletion, and gene rearrangement. Significant progress has been made to elucidate the molecular mechanisms that determine thyroid tumor development and progression (Farid et al., 1994; Segev et al., 2003) . The alterations of mitochondrial DNA (mtDNA) has received much less attention, even though higher copy numbers of mitochondria have been found in thyroid carcinomas and the mutational rate of mtDNA is at least 10 times higher than nuclear DNA due to its continuous exposure to high levels of reactive oxygen species (ROS) generated during oxidative phosphorylation and lack of efficient DNA repair mechanisms (Stefaneanu and Tasca, 1979; Wallace, 1994 Wallace, , 1999 .
mtDNA is the only extrachromosomal DNA in humans. It is a small (16 569 bp), circular, doublestranded DNA that encodes 13 essential protein subunits of the oxidative phosphorylation systems or respiratory chain, two ribosomal RNAs (12S and 16S), and 22 transfer RNAs required for protein synthesis (Eng et al., 2003) . In addition, there is a noncoding region called D-loop, which contains regulatory sequences controlling both replication and transcription of mtDNA. Apart from its role in energy and ROS production, mitochondria is also involved in apoptosis (Eng et al., 2003) .
High incidence of somatic mtDNA mutations has been reported in several types of tumors, including colorectal (70%), bladder (64%), head and neck (46%), lung (43%), ovarian (60%), and pancreatic cancers (80%) (Polyak et al., 1998; Fliss et al., 2000; Jones et al., 2001; Liu et al., 2001) . Yeh et al. (2000) recently screened 21 thyroid tumor samples for mtDNA mutation (covering 25% of the mitochondrial genome) by two-dimensional gene scanning (TDGS) followed by DNA sequencing. They found somatic mutations in only three out of 13 samples with papillary thyroid carcinoma (23%). The frequency of mtDNA mutation appears to be lower in thyroid tumors as compared to those of other tumor types.
In the present study, we investigated 24 thyroid tumors and four tumor cell lines [ARO (derived from human anaplastic thyroid carcinoma), ARO-met2 (derived from ARO with high metastatic potential), NPA (poorly differentiated human papillary thyroid carcinoma), and SW579 (anaplastic thyroid carcinoma)] for mtDNA mutation and performed flow cytometry analysis of mitochondria respiratory function in the thyroid tumor cell lines harboring nonsynonymous mtDNA sequence changes.
We sequenced the entire coding region of mtDNA from 24 thyroid tumor specimens and four thyroid cancer cell lines. A high number of sequence variations were detected by comparing our sequence data with those recoded in the mitochondrial databank and other databases (Tables 1 and 2 ). A total of 14 nonsynonymous mtDNA sequence variants (resulted in aminoacid change) were detected: 11 in the primary tumors and three in the cell lines (Tables 1 and 3 ). Most of them (12/14; 85.7%) were not present in 119 normal controls from the same ethnic background as the disease patients (Bosley et al., 2004) . The only two nonsynonymous sequence variants present in both PTC and normal population controls are at the nucleotide position 5206 in ND2 gene and 12403 in ND5 gene, respectively. Interestingly, the conservation of these two nucleotides among different species was low, indicating that the changes of amino acid may not result in the significant changes of protein function and may represent a rare polymorphism in this ethnic group.
We also detected 36 synonymous mtDNA sequence variants (did not alter amino-acid sequence): three were novel and 33 were previously reported in the mitochondrial databank (http://www.mitomap.org). All synonymous mtDNA sequence variants were also present in our normal control population (Table 2) . Although automated direct sequencing is not sensitive enough to identify low copy number of mtDNA variants (does not allow to determine with certainty if the sequence variants are homoplasmic or not), it is likely that most sequence variants are homoplasmic given the fact that only one signal can be detected in all but two cases where two signals could be individualized (Table 1, Figure 1 ).
Since the data bases search provided only preliminary evidence for mutations and it could not differentiate somatic mutations from rare germline variants, we next tried to determine whether those nonsynonymous mtDNA sequence variants present in thyroid tumor specimens would be present in the normal tissues of the same patient such as peripheral lymphocytes or lymph nodes from paraffin blocks in the pathology archives. As shown in Tables 1 and 3 , seven of the sequence variants (5298, 5408, 7476, 9948, 11126, 13514, and 14417) were present only in the tumor specimens and not in the matched normal tissues, thus considered to be somatic mutations. Among these, six mutations were found in PTC samples and one in benign goiter. The 5298 mutation (A-G, Ile-Val in ND2 gene) was present in two separate PTC samples and the double 5298 and 13580 (C-G, Ala-Gly in ND5 gene) mutation was found in one PTC sample (Table 3 ). The majority of the mutations was involved in genes located in the complex I of the mitochondrial genome. Most mutations were nucleotide substitutions resulting in missense mutations: The number in parenthesis represents the percentage of patients with this particular mutation. This was calculated by dividing the number of patient with a certain mitochondrial mutation/total number of patients tested (n ¼ 24) Â 100%. The same was done for the controls. Interspecies conservation analysis: the amino-acid sequences obtained here were compared with the published sequences (http://us.expasy.org) for human, rat, bovine, chicken, mouse, Drosophila, chimpanzee, ostrich, cat, dog, horse, whale, seal, and chloroplast. The sequence alignments were performed using BioEdit software. Somatic mtDNA sequence changes: sequence variants found at the particular location in the tumor but not in the matched normal samples were considered as somatic mutations. The matched normal tissues were obtained from peripheral lymphocytes or lymph nodes from paraffin blocks in the pathology archives mtDNA mutation in thyroid carcinoma KK Abu-Amero et al either A-G or C-T transitions. One mutation was single base pair deletion causing a nonsense mutation in the ND2 gene (Figure 1 ). To further investigate whether there is a defect in mitochondria respiratory function involving mitochondrial complex I activity in thyroid cancer cell lines, we performed flow cytometric analysis of the thyroid cancer cell lines ARO and SW579. This technique is based on the observation that normal cells have a basal level of superoxide generation, leading to a reproducible level of oxidation of dihydroethidium (DE) to ethidium, which can be quantified by flow cytometer (Williams et al., 1999; Setterfield et al., 2002) . In the normal setting, inhibition by Rotenone (complex I-specific inhibitor) will increase intracellular superoxide levels and therefore increase intracellular ethidium levels, resulting in an elevation of detected fluorescence. However, a pathologic mtDNA mutation in the genes coding for the complex I will likely to inhibit complex I function and cause a greater production of superoxide anions, which leads to a higher basal level of ethidium fluorescence signal. Inhibition with Rotenone will then cause less changes in detected fluorescence since complex I activity is already compromised. As shown in Figure 2 , baseline fluorescence signal was higher in both thyroid cancer cell lines as compared to the control B lymphoblasts (40 vs 30). Fluorescence signal increased approximately threefold in control cells after incubation with the complex I inhibitor Rotenone (20 mM), whereas both thyroid cancer cell lines showed no increase in fluorescence after inhibition, implying that complex I activity was already inhibited by the mtDNA mutations.
We have sequenced 92% of the mitochondrial genome, the entire coding region of mtDNA, and identified somatic mutations in 36.8% of primary papillary thyroid carcinomas, and 25% of multinodular hyperplasias. The majority of the mutations were either A-G or C-T transitions. This kind of mutations is consistent with the known mutagenic spectra of oxidative damage to DNA resulting from the ROS generated in mitochondria (Beckman and Ames, 1997; Cadet et al., 1997; Croteau and Bohr, 1997) .
Thyroid carcinomas are oncocytic tumors characterized by their high abundance of mitochondria. Yeh et al. (2000) found three somatic mtDNA mutations of 13 PTC (23%) and we found seven somatic mutations of 19 PTC (36.8%) examined. Ma´ximo et al. (2002) conducted 
Novelty of sequence changes was established by comparison with those in the mtDNA databases as described in the footnote c of Table 1 (Chagnon et al., 1999) and atypical mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) (Corona et al., 2001) , respectively. To our knowledge, MELAS is only associated with mtDNA germline mutations and not somatic mutations. Therefore, it is quite possible that nt-13514 mutation is associated with PTC in its somatic form and MELAS in its germline form (Abu-Amero et al., 2004). Although we could not determine the nature of the sequence changes (nt-13831, 11919, and 12634) in the thyroid cell lines (polymorphism or mutation) and (nt-14430) in one PTC sample (no matched normal tissue available), they might be mutations given the fact that these variants were not present in the mitochondrial databanks (novel sequence variants) nor in the normal population control. Furthermore, the interspecies conservation of these nucleotides is high, suggesting that the change of amino acids may be pathogenic. Lastly, a severe defect in complex I activity was found in ARO and SW579 thyroid cancer cell lines by flow cytometry analysis, possibly caused by the mtDNA sequence variants nt-13831 and 12634, respectively. These findings provide a critical link between accumulation of mtDNA mutations, which results in elevated levels of ROS inside mitochondria, and carcinogenesis (Singh, 2004) . A recent study has indicated that higher levels of a b c d Figure 1 Detection of mtDNA mutations in PTC samples by sequencing analysis. The entire coding region of the mitochondrial genome for patients and controls were amplified in 24 separate polymerase chain reactions (PCRs) using single set cycling conditions (Rieder et al., 1998) . Each successfully amplified fragment was directly sequenced using the BigDye Terminator V3.1 Cycle Sequencing kit, and samples were run on the ABI prism 3100 sequencer. ROS generated in mitochondria is capable of inducing nuclear DNA damage, possibly extended to tumor suppressor genes and oncogenes (Hartman et al., 2004) . In addition, a mechanism decreasing oxidative metabolism during normal cell division and growth is expected to direct substrates towards biosyntheses rather than towards complete oxidation to CO 2 . Therefore, any event decreasing oxidative phosphorylations (OXPHOS) could provide a proliferating advantage to a transformed or tumor cell in an oxidative tissue. In accordance with this, Simonnet et al. (2002) showed that a low mitochondrial respiratory content correlates with faster tumor growth and aggressiveness in renal cell carcinoma. In addition to the nonsynonymous sequence changes, we also detected 36 synonymous mtDNA sequence changes predicted not to alter their corresponding amino acids. Although we did not determine whether these synonymous sequence changes were somatic or germ line, Yeh et al. (2000) have shown that the distribution and spectra of nonsomatic mitochondrial gene variants seem to differ between patients with thyroid cancer and normal individuals, with complex I variants favored among cancer patients. Their results were confirmed by Ma´ximo et al. (2002) . The frequency of the mutation in our study may be an underestimate since we did not screen the noncoding region of the mitochondrial genome, the so-called D-loop region. Frequent somatic mutations in D-loop have been reported in several other tumors such as cancers of prostate (Jeronimo et al., 2001) , breast (Parrella et al., 2001) , and ovaries (Liu et al., 2001) . Mutational hot spot has also been found in this region in contrast to other regions of mtDNA where no mutational hot spot could be detected. Indeed, Ma´ximo et al. (2002) have found high frequent somatic mutations of both benign (50.0%, 15 of 30) and malignant thyroid tumors (47.2%, 17 of 36) in the D-loop region. Among 19 PTC samples, they found nine somatic mutations (47.4%) in the D-loop region. When all the somatic mutations found in the Dloop and all mtDNA coding genes were combined, the mutation rate was much higher in PTC: 50% (13/26).
Mitochondria have traditionally been viewed as the powerhouse organelles in eucaryotic cells, playing a major role in energy production. The involvement of mitochondria in apoptosis has prompted recent investigations into its role in tumorigenesis. Indeed, many somatic mutations have been identified in different kinds of tumors. It is generally recognized that somatic mutations suggest pathogenecity. In principle, these mutations could contribute to neoplastic transformation by changing cellular energy capacities, increasing mitochrondrial oxidative stress, and modulating apoptosis. However, the significance of each individual mutation on the mitochrondrial function and tumorigenesis is unknown. A recent study by Takano et al. (2000) has demonstrated increased expression of several mitochondrial genes (ND1, ND2, ND4, ND3, and ATP6) in thyroid carcinoma by serial analysis of gene expression (SAGE). It is tempting to speculate that overexpression of mitochondrial genes may result from mtDNA mutations. Indeed, functional analysis of mutant mtDNA in relation to cell behavior, proliferation, and apoptosis is warranted in order to determine the significance of these mutations and their association with tumorigenesis. Flow cytometric analysis of mitochondria respiratory function in SW579 and ARO thyroid cancer cell lines. ARO and SW579 were washed twice in 10 ml phosphate-buffered saline (PBS) and suspended in 1 ml of PBS. Each cell suspension was divided into two tubes, each having 500 ml (1 Â 10 6 cells). One tube was treated with the complex I inhibitor Rotenone (20 mM; Sigma) and incubated for 20 min at 371C. All tubes were then incubated with 10 mM dihydroethidium (DE; Molecular Probes) for 15 min at room temperature. Cells were immediately analysed in a FACScan flow cytometer. Normal human B-cell lymphoblasts were treated and analysed in the same way as the SW579 and ARO cell lines. In summary, we have found high frequency of somatic mitochondrial gene mutations in both benign and malignant thyroid tumor specimens (36.8% in papillary carcinomas and 25% in benign multinodular hyperplasias). Flow cytometry analysis of mitochondria respiratory function in the thyroid tumor cell lines, where sequence variants nt-13831 and nt-12634 were found, revealed a severe defect in mitochondrial complex I activity. These previously overlooked genetic alterations in tumor cells might have significant effects on the cellular processes mediated by mitochondria and thyroid tumorigenesis.
